The pharmaceutical companies behind the biggest weight-loss drugs shook up their lobbying operations during the first six months of President Donald Trump’s second term.
Last week, the companies appeared to get a sign that their strategy is working, with reports that the administration is considering covering weight-loss medication under Medicaid and Medicare.
Novo Nordisk, which makes Ozempic and Wegovy, and Lilly, the maker of Mounjaro and Zepbound formerly known as Eli Lilly, have added firms close to the administration since Trump took office in January.